🟢 Icecure Medical is trading 8.8% up in pre-market with no clear catalyst identified

Icecure Medical is trading at $1.68, up 8.79% in pre-market on October 6, with no clear company-specific catalyst identified.

• Its investor-relations page lists September 10 as its latest press release, announcing Chinese regulatory approval for ProSense; that news predates this move.
• Major indices are up less than 0.5%, which does not clearly explain the move.
• A prior after-hours report noted a 7.1% gain, also without an identified company-specific catalyst.